-
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;13:231-7. -
Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks.
Matias A, Huggon I, Areias JC, Montenegro N, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;14:307-10. -
The umbilical artery pulsatility index in the first trimester: is there an association with increased nuchal translucency or chromosomal abnormality?
Brown R, Di Luzio L, Gomes C, Nicolaides KH.
Ultrasound Obstet Gynecol 1998;12:244-7. -
Fetal heart rate and umbilico-placental Doppler flow velocity waveforms in early pregnancies with a chromosomal abnormality and/or an increased nuchal translucency thickness.
Jauniaux E, Gavrill P, Kuhn P, Kurdi W, Hyett J, Nicolaides KH.
Hum Reprod 1996;11:435-9. -
Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness.
Noble PL, Abraha HD, Snijders RJ, Sherwood R, Nicolaides KH.
Ultrasound Obstet Gynecol 1995;6:390-5. -
Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy.
Brizot ML, Snijders RJ, Butler J, Bersinger NA, Nicolaides KH.
Br J Obstet Gynaecol 1995;102:127-32.